Media coverage about Impax Laboratories (NASDAQ:IPXL) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Impax Laboratories earned a news sentiment score of 0.17 on Accern’s scale. Accern also gave news headlines about the specialty pharmaceutical company an impact score of 47.2634847330364 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Here are some of the news headlines that may have effected Accern’s rankings:

Shares of Impax Laboratories (NASDAQ IPXL) opened at $16.67 on Friday. The stock has a market cap of $1,241.40, a price-to-earnings ratio of 24.63, a price-to-earnings-growth ratio of 1.06 and a beta of 0.99. The company has a quick ratio of 1.32, a current ratio of 1.81 and a debt-to-equity ratio of 1.59. Impax Laboratories has a fifty-two week low of $7.75 and a fifty-two week high of $25.70.

Impax Laboratories (NASDAQ:IPXL) last announced its quarterly earnings results on Thursday, November 9th. The specialty pharmaceutical company reported $0.23 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.03. The firm had revenue of $206.40 million for the quarter, compared to analyst estimates of $208.38 million. Impax Laboratories had a negative net margin of 56.59% and a positive return on equity of 9.06%. The business’s revenue for the quarter was down 9.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.37 EPS. equities research analysts forecast that Impax Laboratories will post 0.63 earnings per share for the current fiscal year.

A number of analysts have issued reports on the stock. Canaccord Genuity set a $19.00 target price on shares of Impax Laboratories and gave the company a “hold” rating in a research note on Wednesday, August 9th. UBS AG lifted their target price on shares of Impax Laboratories from $12.00 to $16.00 and gave the company a “sell” rating in a research note on Monday, October 30th. Cantor Fitzgerald set a $20.00 target price on shares of Impax Laboratories and gave the company a “buy” rating in a research note on Wednesday, August 9th. Citigroup Inc. lifted their target price on shares of Impax Laboratories to $23.00 and gave the company a “buy” rating in a research note on Tuesday, September 19th. Finally, Zacks Investment Research cut shares of Impax Laboratories from a “hold” rating to a “strong sell” rating in a research note on Monday, July 24th. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and five have assigned a buy rating to the company’s stock. Impax Laboratories has an average rating of “Hold” and a consensus price target of $19.60.

COPYRIGHT VIOLATION WARNING: “Impax Laboratories (IPXL) Getting Somewhat Favorable Press Coverage, Analysis Finds” was reported by Daily Political and is the property of of Daily Political. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/11/17/impax-laboratories-ipxl-getting-somewhat-favorable-press-coverage-analysis-finds.html.

About Impax Laboratories

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Insider Buying and Selling by Quarter for Impax Laboratories (NASDAQ:IPXL)

Receive News & Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.